Nav: Home

VA study evaluates quality indicators for hormone therapy in menopausal women

March 07, 2019

March 7, 2019 - Improvements are needed in VA's prescribing of hormone therapy for menopausal women veterans, concludes a study in the Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

"Our findings underscore the need to develop and implement innovations for providing practitioners with point-of care information and decision support to ensure patients are receiving guideline-adherent care in health care settings, including VA," comments lead author Kristina M. Cordasco, MD, MPH, of VA Greater Los Angeles Health System.

Quality Indicators Show Need for Improvement in Hormone Therapy for Women Veterans

The researchers developed a set of seven quality indicators to assess how well hormone therapy prescribed for women veterans met accepted, evidence-based guidelines. Recommendations for systemic (oral) hormone therapy in menopausal women can be complex. Estrogen therapy is effective for menopausal symptoms, especially hot flashes, and can reduce the risk of fractures in women with osteoporosis.

However, hormone therapy can increase the risk of certain cancers, blood clots, and other health problems. It should not be used for other types of menopausal symptoms, such as sexual dysfunction or depression; or in women with certain health issues (contraindications), such as breast cancer or heart disease. In addition, in women with a uterus (those who haven't had a hysterectomy), the hormone progesterone should always be given with estrogen to protect against endometrial cancer.

Dr. Cordasco and colleagues used their quality indicators to assess adherence to guidelines for hormone therapy in women veterans. The analysis included a total of 355 systemic hormone prescriptions provided to 266 women at four VA centers.

Across the seven quality indicators, average adherence to systemic hormone therapy guidelines was 58 percent, with similar rates for new and renewal prescriptions. About three-fourths of new prescriptions documented a specific indication for hormone therapy consistent with current guidelines. However, in more than one-fourth of cases, there was no documentation of the absence of contraindications.

In more than half of new prescriptions, the initial prescription for estrogen was higher than the generally recommended starting dose, without documented reasons for this high dose . Most renewal prescriptions stayed at this high dose, or escalated it without a documented reason. In eight out of 116 cases, progesterone was not initially prescribed along with estrogen in women with an intact uterus, potentially transiently increasing their risk of endometrial cancer.

Women's health issues can pose a challenge in the VA system, where only about ten percent of patients are women. To address this challenge, VA channels patients into panels of Designated Women's Health Providers (DWHPs). Most hormone therapy prescriptions were written by DWHPs, but their performance in following guidelines was similar to that of other providers.

The study suggests that nearly 40 percent of prescriptions for systemic hormone therapy for menopausal women in the VA system aren't consistent with evidence-based guidelines. It is unknown how this finding compares to guideline adherence in healthcare settings outside VA, as such studies have not been conducted. However, this finding is "unfortunately consistent with prior work in other conditions and populations," the researchers write.

The quality indicators developed for the study should be used to assess prescriptions in other patient populations and other healthcare systems, Dr. Cordasco and colleagues believe. They write, "Our findings lay important foundation for interventions for improving guideline adherence." The researchers call for further studies of the underlying reasons for variations in care, along with evaluation of computerized decision support or other tools to ensure safe use of hormone therapy in women veterans.
Click here to read "Veterans Health Administration Primary Care Provider Adherence to Prescribing Guidelines for Systemic Hormone Therapy in Menopausal Women"

DOI: 10.1097/JHQ.0000000000000183

About the Journal for Healthcare Quality

The Journal for Healthcare Quality (JHQ), a peer-reviewed journal, is an official publication of the National Association for Healthcare Quality. (NAHQ). JHQ is a professional forum that continuously advances healthcare quality practice in diverse and changing environments, and is the first choice for creative and scientific solutions in the pursuit of healthcare quality. The Journal publishes scholarly articles that are targeted to leaders of all healthcare settings, leveraging applied research and producing practical, timely and impactful evidence in healthcare system transformation.

About NAHQ

NAHQ is the leader in healthcare quality competencies. NAHQ provides a strategic advantage to healthcare professionals and the organizations they serve by developing and evolving competencies in healthcare quality that result in better patient and financial outcomes to support the goals of healthcare value. NAHQ offers the industry standard certification in healthcare quality, extensive educational programming, networking opportunities, and career resources to help healthcare professionals meet the challenges they face. Learn more about NAHQ at

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information, software solutions, and services for the health, tax & accounting, finance, risk & compliance, and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer, headquartered in the Netherlands, reported 2017 annual revenues of €4.4 billion. The company serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide.

Wolters Kluwer Health is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

Wolters Kluwer Health

Related Estrogen Articles:

Placenta transit of an environmental estrogen
The human foetus is considered to be particularly sensitive to environmental contaminants.
Estrogen improves Parkinson's disease symptoms
Brain-selective estrogen treatment improves the symptoms of Parkinson's disease in male mice, according to new research published in JNeurosci.
The sneaky way estrogen drives brain metastasis in non-estrogen-dependent breast cancers
University of Colorado Cancer Center study shows that while estrogen doesn't directly affect triple-negative breast cancer cells, it can affect surrounding brain cells in ways that promote cancer cell migration and invasiveness
Estrogen made by neurons important to making memories
Estrogen in the brain is important to keep neurons communicating and memories being made, scientists report.
New study demonstrates effectiveness and safety of vaginal estrogen
Despite its proven effectiveness in treating the genital symptoms of menopause, low-dose vaginal estrogen therapy remains underused largely because of misperceptions regarding its safety.
More Estrogen News and Estrogen Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...